| LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men CA Hagemann, MS Jensen, S Holm, LS Gasbjerg, S Byberg, ... Cell Reports Medicine 3 (4), 2022 | 46 | 2022 |
| Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity K Huynh, M Klose, K Krogsgaard, J Drejer, S Byberg, S Madsbad, ... European Journal of Endocrinology 186 (6), 687-700, 2022 | 23 | 2022 |
| Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis S Byberg, J Futtrup, M Andreassen, J Krogh Endocrine connections 8 (10), 1395-1404, 2019 | 19 | 2019 |
| Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report S Byberg, B Abrahamsen, M Kassem, S Ralston, P Schwarz Journal of medical case reports 12, 1-6, 2018 | 16 | 2018 |
| Necrotizing fasciitis and meningitis due to Streptococcus pneumoniae serotype 9 N: a case report N Hovmand, S Byberg, MB Larsen, D Podlekareva, DL Buck, BR Hansen BMC Infectious Diseases 19, 1-5, 2019 | 6 | 2019 |
| LEAP2 is associated with cardiometabolic markers but is unchanged by antidiabetic treatment in people with prediabetes S Byberg, MB Blond, S Holm, H Amadid, LB Nielsen, KKB Clemmensen, ... American Journal of Physiology-Endocrinology and Metabolism 325 (3), E244-E251, 2023 | 5 | 2023 |
| The dietary regulation of LEAP2 depends on meal composition in mice AKJ Gradel, SK Holm, S Byberg, M Merkestein, WFJ Hogendorf, ML Lund, ... The FASEB Journal 37 (6), e22923, 2023 | 5 | 2023 |
| Weight loss, improved body composition and fat distribution by tesomet in acquired hypothalamic obesity KD Huynh, MC Klose, K Krogsgaard, J Drejer, S Byberg, S Madsbad, ... Journal of the Endocrine Society 5 (Supplement_1), A64-A65, 2021 | 5 | 2021 |
| Ketone monoester increases circulating levels of LEAP2 and decreases appetite in healthy men SK Holm, ET Vestergaard, NB Zubanovic, S Byberg, C Clemmensen, ... Diabetes, Obesity and Metabolism 25 (7), 2023-2027, 2023 | 2 | 2023 |
| Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity I Matias, EW Lehmann, P Zizzari, S Byberg, D Cota, SS Torekov, C Quarta Journal of Endocrinological Investigation 47 (5), 1289-1294, 2024 | 1 | 2024 |
| A randomized-controlled trial of tesomet resulted in significant weight loss in hypopituitary patients with hypothalamic obesity K Huynh, M Klose, K Krogsgaard, J Drejer, S Byberg, S Madsbad, ... Endocrine Abstracts 70, 2020 | 1 | 2020 |
| GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly MH Jensen, LS Gasbjerg, K Skov-Jeppesen, JCB Jacobsen, SS Poulsen, ... The Journal of Clinical Endocrinology & Metabolism, dgae583, 2024 | | 2024 |
| ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults … M Klose, K Huynh, K Krogsgaard, J Drejer, D Pharm, S Byberg, ... Journal of the Endocrine Society 6 (Supplement_2), A509-A509, 2022 | | 2022 |
| Significant weight loss resulted in reduced levothyroxine requirements during a tesomet trial of hypopituitary patients with acquired hypothalamic obesity M Klose, K Huynh, J Tfelt, K Krogsgaard, J Drejer, S Byberg, S Madsbad, ... Endocrine Abstracts 81, 2022 | | 2022 |
| Atherosclerotic cardiovascular disease among migrants with type 2 diabetes: a nationwide register-based study GS Andersen, S Byberg, ASD Bjorkman, AA Isaksen, H Amadid, ... DIABETOLOGIA 63 (SUPPL 1), S142-S143, 2020 | | 2020 |
| Necrotizing fasciitis and meningitis due to Streptococcus pneumoniae serotype 9 N N Hovmand, S Byberg, MB Larsen, D Podlekareva, DL Buck, BR Hansen Hemoglobin (g/dL) 13, 0, 2019 | | 2019 |
